Trial · NCT02421588
Adverse events244
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 244
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Lurbinectedin | 12 | 219 | 22 |
| other | Hypertension | Vascular disorders | Control (PLD or Topotecan) | 4 | 213 | 9 |
| other | Weight decreased | Investigations | Lurbinectedin | 10 | 219 | 14 |
| other | Weight decreased | Investigations | Control (PLD or Topotecan) | 14 | 213 | 16 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Lurbinectedin | 17 | 219 | 19 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Control (PLD or Topotecan) | 26 | 213 | 33 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Lurbinectedin | 29 | 219 | 37 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Control (PLD or Topotecan) | 23 | 213 | 34 |
| other | Anaemia | Blood and lymphatic system disorders | Lurbinectedin | 57 | 219 | 155 |
| other | Anaemia | Blood and lymphatic system disorders | Control (PLD or Topotecan) | 77 | 213 | 201 |
| other | Leucopenia | Blood and lymphatic system disorders | Lurbinectedin | 23 | 219 | 39 |
| other | Leucopenia | Blood and lymphatic system disorders | Control (PLD or Topotecan) | 21 | 213 | 38 |
| other | Neutropenia | Blood and lymphatic system disorders | Lurbinectedin | 73 | 219 | 167 |
| other | Neutropenia | Blood and lymphatic system disorders | Control (PLD or Topotecan) | 89 | 213 | 211 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Lurbinectedin | 20 | 219 | 46 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Control (PLD or Topotecan) | 39 | 213 | 77 |
| other | Headache | Nervous system disorders | Lurbinectedin | 26 | 219 | 36 |
| other | Headache | Nervous system disorders | Control (PLD or Topotecan) | 9 | 213 | 10 |
| other | Neuropathy peripheral | Nervous system disorders | Lurbinectedin | 19 | 219 | 32 |
| other | Neuropathy peripheral | Nervous system disorders | Control (PLD or Topotecan) | 15 | 213 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02421588/events